These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33916925)

  • 1. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
    Pęksa R; Kunc M; Popęda M; Piątek M; Bieńkowski M; Żok J; Starzyńska A; Perdyan A; Sowa M; Duchnowska R; Biernat W
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.
    Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4131-4139. PubMed ID: 36042047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
    Schoop H; Bregenzer A; Halske C; Behrens HM; Krüger S; Egberts JH; Röcken C
    Transl Oncol; 2020 Feb; 13(2):165-176. PubMed ID: 31865179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
    Zong L; Mo S; Sun Z; Lu Z; Yu S; Chen J; Xiang Y
    Mod Pathol; 2022 Feb; 35(2):266-273. PubMed ID: 34493823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
    Tang Y; Li G; Wu S; Tang L; Zhang N; Liu J; Zhang S; Yao L
    Oncol Lett; 2018 Apr; 15(4):4988-4996. PubMed ID: 29552135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
    J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells.
    Pęksa R; Kunc M; Czapiewski P; Piątek M; Hać S; Radecka B; Biernat W
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
    Böger C; Behrens HM; Krüger S; Röcken C
    Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
    Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
    Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
    Mei Y; Bi WL; Agolia J; Hu C; Giantini Larsen AM; Meredith DM; Al Abdulmohsen S; Bale T; Dunn GP; Abedalthagafi M; Dunn IF
    Pituitary; 2021 Jun; 24(3):359-373. PubMed ID: 33492612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
    Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
    Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.
    Itoh S; Yugawa K; Shimokawa M; Yoshiya S; Mano Y; Takeishi K; Toshima T; Maehara Y; Mori M; Yoshizumi T
    BJS Open; 2019 Aug; 3(4):500-508. PubMed ID: 31388642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.